Search


Current filters:
Start a new search
Add filters:

Use filters to refine the search results.

Results 1-10 of 34 (Search time: 0.031 seconds).
Issue DateTitleAuthor(s)
2019CANOPY-1: A phase III, placebo-controlled study of pembrolizumab (PEM) plus platinum-based doublet chemotherapy (Ctx) with/without canakinumab in untreated patients (pts) with stage IIIB/IIIC-IV NSCLCTAN, D. S. W.; KIM, T. M.; SOLOMON, B. J.; TAN, W. L.; YU, C-J.; GEATER, S.; CASTRO JR., G. De; GREYSTOKE, A.; FELIP, E.; JOHNSON, B. E.; DEUDON, S.; LOUVEAU, A-L.; PASSOS, V. Q.; CHO, B. C.
2019CANOPY phase III program: Three studies evaluating canakinumab in patients with non-small cell lung cancer (NSCLC)PAZ-ARES, L.; GARON, E. B.; ARDIZZONI, A.; BARLESI, F.; CHO, B. C.; CASTRO JUNIOR, G. de; MARCHI, P. De; FELIP, E.; GOTO, Y.; GREYSTOKE, A.; LU, S.; LIM, D. W-T.; PAPADIMITRAKOPOULOU, V. A.; RECK, M.; SOLOMON, B. J.; SPIGEL, D.; TAN, D. S. W.; THOMAS, M.; YANG, J. C-H.; JOHNSON, B.
2019Phase II/III blood first assay screening trial (BFAST) in patients (pts) with treatment-naive NSCLC: Initial results from the ALK plus cohortGADGEEL, S. M.; MOK, T. S. K.; PETERS, S.; ALEXANDER, J. A. A.; LEIGHL, N. B.; SRIURANPONG, V.; PEROL, M.; CASTRO JR., G. De; NADAL, E.; MARINIS, F. De; HAN, J-Y.; YAN, M.; RIEHL, T.; SCHLEIFMAN, E.; PAUL, S. M.; MOCCI, S.; SHAMES, D.; MATHISEN, M. S.; DZIADZIUSZKO, R.
2019Association between tissue TMB (tTMB) and clinical outcomes with pembrolizumab monotherapy (pembro) in PD-L1-positive advanced NSCLC in the KEYNOTE-010 and-042 trialsHERBST, R. S.; LOPES, G.; KOWALSKI, D. M.; NISHIO, M.; WU, Y-L.; CASTRO JUNIOR, G. de; BAAS, P.; KIM, D-W.; GUBENS, M. A.; CRISTESCU, R.; AURORA-GARG, D.; ALBRIGHT, A.; AYERS, M.; LOBODA, A.; LUNCEFORD, J.; KOBIE, J.; LUBINIECKI, G. M.; PIETANZA, M. C.; PIPERDI, B.; MOK, T. S. K.
2019Outcomes with pembrolizumab (pembro) monotherapy in patients (pts) with PD-L1-positive NSCLC with brain metastases: Pooled analysis of KEYNOTE-001,-010,-024, and-042MANSFIELD, A. S.; HERBST, R. S.; CASTRO JR., G.; HUI, R.; PELED, N.; KIM, D-W.; NOVELLO, S.; SATOUCHI, M.; WU, Y-L.; GARON, E. B.; RECK, M.; ROBINSON, A. G.; SAMKARI, A.; PIPERDI, B.; EBIANA, V.; LIN, J.; MOK, T. S. K.
2019Real world data on adjuvant chemotherapy for high-risk stage II colorectal cancer: The role of tumour sideCARVALHO, C. S. Araujo de; MONIZ, C. M. V.; WATARAI, G. Y.; CRESPO, J. A. R.; NOGUEIRA, P. V. D. S.; MARTINEZ, J. K.; MORAES, P. M. G. D.; BONADIO, R. R. D. C. C.; BRAGHIROLI, M. I. F. M.; SABBAGA, J.; HOFF, P. M. G.
2012PROGNOSTIC FACTORS AND TREATMENT OF CERVICAL CANCER (CC) IN ELDERLYCAIRES, I. Q. S.; LIMA, R. C. A. D.; BARROSO-SOUSA, R.; ANDRADE, E. M. P. D.; SILVA, J. R. D.; SANCHEZ, F. B.; HOFF, P. M.; DIZ, M.
2012ORAL METRONOMIC CYCLOPHOSPHAMIDE IN PATIENTS WITH METASTATIC CASTRATION-RESISTANT PROSTATE CANCER STRATIFIED BY PRIOR DOCETAXEL THERAPYBARROSO-SOUSA, R.; CHAVES, A. C. R.; FONSECA, L. G.; CASTRO JR., G. De; DZIK, C.; HOFF, P. M.
2012THE ENCHANTTM TRIAL: AN OPEN LABEL MULTICENTER PHASE 2 WINDOW OF OPPORTUNITY STUDY EVALUATING GANETESPIB (STA-9090) MONOTHERAPY IN WOMEN WITH PREVIOUSLY UNTREATED METASTATIC HER2 POSITIVE OR TRIPLE NEGATIVE BREAST CANCER (TNBC)CAMERON, D.; MANO, M. S.; VUKOVIC, V.; TEOFILOVICI, F.; BRADLEY, R.; AWADA, A.
2012THE QUALITY OF SAMPLE SIZE CALCULATION (SSC) REPORTING IN CANCER CLINICAL TRIALSBARIANI, G. M.; FERRARI, A. C. R. C.; HOFF, P. M.; ARAI, R.; PRECIVALE, M.; RIECHELMANN, R. P.